Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan

Despite the initial success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in prevention of symptomatic and severe diseases, booster vaccination has become increasingly important with the advent of variants with immune-escaping capacity. Herein, we report the safety and imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonoyama, Takuhiro, Kamitani, Akari, Shibata, Risa Y., Seki, Naomi M., Omoto, Shinya, Igarashi, Kenji, Ariyasu, Mari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Regular paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562875/
https://www.ncbi.nlm.nih.gov/pubmed/37822891
http://dx.doi.org/10.1016/j.jvacx.2023.100390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562875/
https://www.ncbi.nlm.nih.gov/pubmed/37822891
http://dx.doi.org/10.1016/j.jvacx.2023.100390

Ejemplares similares